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David A. Brown, PhD
Background—-Manifestations of reperfusion injury includemyocyte death leading to infarction, contractile dysfunction, and vascular
injury characterized by the “no-reflow” phenomenon. Mitochondria-produced reactive oxygen species are believed to be centrally
involved in each of these aspects of reperfusion injury, although currently no therapies reduce reperfusion injury by targeting
mitochondria specifically.
Methods and Results—-We investigated the cardioprotective effects of a mitochondria-targeted peptide, Bendavia (Stealth Pep-
tides), across a spectrum of experimental cardiac ischemia/reperfusion models. Postischemic administration of Bendavia reduced
infarct size in an in vivo sheep model by 15% (P=0.02) and in an ex vivo guinea pig model by 38% to 42% (P<0.05). In an in vivo
rabbit model, the extent of coronary no-reflow was assessed with Thioflavin S staining and was significantly smaller in the Bendavia
group for any given ischemic risk area than in the control group (P=0.0085). Myocardial uptake of Bendavia was ≈25% per minute,
and uptake remained consistent throughout reperfusion. Postischemic recovery of cardiac hemodynamics was not influenced by
Bendavia in any of the models studied. Isolated myocytes exposed to hypoxia/reoxygenation showed improved survival when
treated with Bendavia. This protection appeared to be mediated by lowered reactive oxygen species–mediated cell death during
reoxygenation, associated with sustainment of mitochondrial membrane potential in Bendavia-treated myocytes.
Conclusions—-Postischemic administration of Bendavia protected against reperfusion injury in several distinct models of in-
jury. These data suggest that Bendavia is a mitochondria-targeted therapy that reduces reperfusion injury by maintaining
mitochondrial energetics and suppressing cellular reactive oxygen species levels. ( J Am Heart Assoc. 2012;1:e001644
doi: 10.1161/JAHA.112.001644.)
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E arly and successful myocardial reperfusion with primarypercutaneous coronary intervention remains the most ef-
fective strategy for reducing the size of amyocardial infarct and
improving clinical outcome. Reperfusion injury is a major issue
in patients who receive percutaneous coronary intervention or
thrombolysis or have spontaneous reperfusion for ST-segment
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myocardial infarction. Two major manifestations of reperfu-
sion injury are myocyte death (infarction) and microvascular
damage (no-reflow). Given that long-term prognosis has been
linked to both size of infarction1–3 and the extent of reflow,4,5
strategies aimed to decrease infarct size or limit the amount
of no-reflow have significant potential as adjuvant therapies.
Reactive oxygen species (ROS) are centrally involved in the
development of infarction and no-reflow. Augmented produc-
tion of ROS during early reperfusion contributes to both my-
ocyte death6,7 and microvascular dysfunction leading to no-
reflow.8,9 Elevated ROS increase the probability of opening
of the mitochondrial permeability transition pore,10 which is
followed by bioenergetic collapse and ultimately cell death.
Given that mitochondrial ROS production is high in early reper-
fusion, therapies that directly (and effectively) target mito-
chondrial ROS production are ideal in this setting. A novel
class of cell-permeable peptides has been developed that
selectively target mitochondria. The Szeto-Schiller (SS) pep-
tides are relatively small water-soluble molecules that contain
a similar structural motif of alternating basic and aromatic
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residues, which allows them to freely cross cell membranes
(despite a 3+ net charge at physiological pH).11 Studies with
fluorescent and radiolabeled SS peptides indicate that they
localize to mitochondria and concentrate at inner mitochon-
drial membranes.12 One particular peptide, Bendavia (an ana-
logue of SS-02 and SS-31; Stealth Peptides), has been shown
to reduce ROS levels in isolated mitochondria and to pro-
tect cultured cells against cell death induced by a variety of
chemical stressors.13 Although these findings are promising,
whether they relate to primary cardiac myocytes exposed to
hypoxia/reoxygenation and translate to large animal models
of ischemia/reperfusion (eg, infarction and no-reflow) is not
known.
The purpose of the present study was to determine
whether Bendavia could protect the myocardium from reper-
fusion injury. In a collaboration that spanned 3 indepen-
dent laboratories, we used large animal models of is-
chemia/reperfusion, isolated perfused hearts, and myocyte
hypoxia/reoxygenation experiments to determine if this
mitochondria-targeting peptide attenuated cell death and
no-reflow.
Methods
The animals used in these studies were maintained in accor-
dance with the Position of the American Heart Association on
Research Animal Use (American Heart Association, 1985) and
the Guide for Care and Use of Laboratory Animals (1996). Pro-
tocols in all 3 laboratories received prior approval by the institu-
tional animal care and use committee of each individual institu-
tion (University of Pennsylvania, Good Samaritan Hospital, and
East Carolina University). All sheep studies were performed by
the Gorman Cardiovascular Research Group at the Glenolden
Research Laboratory, Department of Surgery, University of
Pennsylvania School of Medicine, Glenolden, PA. All rabbit
studies were done in the Kloner Laboratory at the Good Samar-
itan Hospital, University of Southern California, Los Angeles.
Studies using guinea pigs were done in the Brown Labora-
tory at the Brody School of Medicine, East Carolina University,
Greenville, NC.
Ischemia/Reperfusion Injury in Sheep Model
Male Dorsett hybrid sheep were randomly assigned to treat-
ment with vehicle (n=8) or Bendavia (0.05 mg/kg per hour;
n=11). The data are from 2 groups of male Dorsett hybrid
sheep that were entered into a cyclosporine/Bendavia dose-
assessment study. Data from the group of sheep that received
the same dose of Bendavia as the rabbits (0.05 mg/kg per
hour; n=11) and from all sheep treated with vehicle (n=8) are
presented here. Sheep received a preanesthetic regimen of ke-
tamine (10 mg/kg IV over 30 seconds), diazepam (1 mg/kg IV
over 30 seconds), and glycopyrrolate (0.015 mg/kg IV bolus).
Anesthesia was induced with inhaled isoflurane (1% to 3%).
The sheep were pretreated with antiarrhythmic medication: li-
docaine bolus followed by continuous intravenous infusion at
≈0.015 mg/min. A Swan-Ganz pulmonary artery catheter was
inserted through a right internal jugular sheath and “floated”
into the pulmonary artery to monitor pulmonary artery pres-
sure, central venous pressure, and core temperature. A Millar
catheter was inserted into the arterial sheath placed in the
femoral artery to monitor left ventricular (LV) pressure. Body
temperature was maintained between 38.8◦C and 39.0◦C in
both groups throughout the protocol.
To create the myocardial infarction, snares were placed
around the distal left anterior descending coronary artery and
selected branches of the diagonals to achieve an ischemic risk
zone of ≈20% to 25% of the LV. Occlusion of the coronary
vessel(s) lasted 60 minutes and was followed by 180 minutes
of reperfusion. Hemodynamic variables were recorded and an-
alyzed at baseline, at the end of the ischemic period, and after
5 minutes and 180 minutes of reperfusion.
At 30 minutes of ischemia, intravenous infusions of either
Bendavia or placebo were initiated and continued through is-
chemia and until the conclusion of the reperfusion phase.
At the end of 3 hours of reperfusion, the coronary arteries
were religated, and infarct size was assessed as previously
described.14
Statistical Analyses for Sheep Studies
Data summary and statistical analyses were performed with
SAS (Version 9.3, Cary, NC). Differences between area at risk
(AAR) and infarct size were assessed by the Student t test.
Changes in hemodynamic variables over time were analyzed
by repeated-measures analysis of variance (ANOVA). Analysis
of covariance (ANCOVA) was used to test for a group effect on
the regression model of necrotic zone and risk zone in sheep.
Data are expressed as mean±SEM.
No-Reflow and Infarct Size in Rabbit Model
The techniques used for the rabbit model of acute my-
ocardial infarction in the Kloner laboratory have been de-
scribed previously.15 Briefly, anesthetized, open-chest male
New Zealand White rabbits (2.5 to 3.3 kg) were subjected
to 30 minutes of coronary artery occlusion (CAO) followed
by 3 hours of reperfusion. After 15 minutes of stabilization,
baseline hemodynamic parameters and temperatures were ob-
tained, with body temperatures maintained between 37.9◦C
and 38.1◦C throughout all experiments. Rabbits were random-
ized to one of the following 4 groups:
Group 1: treatment at 20 minutes before reperfusion,
0.05 mg/kg per hour of Bendavia, intravenous infusion
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starting at 10 minutes after CAO and continuing through-
out reperfusion
Group 2: treatment at 10 minutes before reperfusion, starting
20minutes after CAO, 0.075mg/kg per hour of Bendavia, in-
travenous infusion for the first 20minutes, then 0.05mg/kg
per hour throughout reperfusion
Group 3: treatment starting immediately before coro-
nary artery reperfusion (1 minute), 0.10 mg/kg per
hour intravenous infusion for the first 20 minutes, then
changed to 0.05 mg/kg per hour of Bendavia throughout
reperfusion
Group 4: saline, an equivalent volume relative to Bendavia
starting at 10 minutes after CAO and continuing throughout
reperfusion.
The total volume infused was <6 mL.
The extent of the no-reflow zone was assessed by stain-
ing with Thioflavin S (Sigma-Aldrich), a fluorescent yellow
dye that stains endothelium and serves as a marker of re-
gional perfusion. Under ultraviolet light, the no-reflow zone
appears as a nonfluorescent, dark area, and regions of per-
fusion appear brightly fluorescent. The risk zone was delin-
eated by Unisperse blue pigment (Ciba-Geigy) and necrosis
by triphenyltetrazolium chloride. Measurements of risk zone,
no-reflow zone, and infarct size were calculated as previously
described.15
Sixty-six rabbits entered the protocol with 64 successful
studies: Group 1, n=15; Group 2, n=17; Group 3, n=17; and
Group 4, n=15. Data from 2 hearts were excluded on the basis
of the prospective exclusion criterion of ischemic risk zone size
(AAR <10% of the LV).
Statistical Analyses for Rabbit Study
Data from the 4 groups were analyzed. In addition, to assess
the overall effects of treatment with Bendavia when adminis-
tered after the onset of CAO but before reperfusion, infarct size
and no-reflowdata from the3 treated groups (n=49)were com-
bined and compared with that from the control group (n=15).
A post hoc analysis was performed with a risk zone exclusion
of <20% of the LV to study a population comparable to the
sheep data.
Data summary and statistical analyses were performed
with SAS (Version 9.3, Cary, NC). LV weight, infarct size,
AAR, and area of no-reflow were compared by ANOVA.
Changes in hemodynamic variableswere analyzed by repeated-
measures ANOVA. ANCOVA was used to test for a group
effect on the regression model of no-reflow zone with risk
zone. Infarct size and no-reflow data from the combined
Bendavia-treated hearts versus control hearts were ana-
lyzed by t test and by ANCOVA. Data are expressed as
mean±SEM.
Ischemia/Reperfusion Injury in Guinea Pigs
Adult male guinea pigs (200 to 300 g) were anesthetized
with a ketamine/xylazine cocktail (85/15 mg/kg, respec-
tively; intraperitoneal delivery). Hearts were excised, placed
on a modified Langendorff apparatus, and instrumented
for the observation of electromechanical function, as pre-
viously described.16,17 Hearts were divided into the follow-
ing treatment groups: (1) control followed by global is-
chemia/reperfusion (n=14); (2) administration of 1 nmol/L
Bendavia in the perfusate beginning 10 minutes before in-
dex ischemia and for the entire reperfusion (n=9); (3) postis-
chemic administration of 1 nmol/L Bendavia for the duration
of reperfusion (n=9); and (4) postischemic administration of
0.2 μmol/L cyclosporine A (n=8). For groups 2 through 4,
experimental compounds were dissolved in Krebs Henseleit
buffer (Sigma-Aldrich) and placed in dedicated buffer reser-
voirs (gassed with 95%/5% O2/CO2, 37◦C). Hearts were ex-
posed to global no-flow ischemia by stopping perfusion for
20 minutes. At the end of the 120-minute reperfusion period,
infarct size and arrhythmia scores were assessed as previously
described.16,17
Myocardial Uptake of Bendavia
A separate group of guinea pigs (n=7) was used to deter-
mine the extent of Bendavia uptake by the myocardium at
baseline and throughout reperfusion. Hearts were perfused
constantly with 1 nmol/L Bendavia as described above, and
coronary effluent was collected through a pulmonary artery
cannula. Samples were collected at baseline (before 20 min-
utes of global no-flow ischemia) and every 15 minutes for the
first hour of reperfusion. At each time point, 2 samples of
perfusate were obtained (1 mL of each): one from the buffer
before entry into the perfusion cannula (input) and the other
from the pulmonary cannula (output). Samples were immedi-
ately mixed with 100 μL of 5% formic acid and snap-frozen in
liquid nitrogen, and Bendavia concentration was subsequently
determined with liquid chromatography–mass spectrometry
(Sciex API4000 LC-MS/MS system coupled with Shimadzu
High-Performance Liquid Chromatography; Medpace Bioan-
alytical Laboratories, Cincinnati, OH). The calibration range
of the assay was 0.1 to 100 ng/mL. Three levels of quality-
control samples at low (0.3 ng/mL), mid (5 ng/mL), and high
(80 ng/mL) concentrations were included in each batch of
analysis. The chromatographic separations were achieved on
a UniverSil 5 μm C18, 100 × 2.1 mm high-performance liq-
uid chromatography column and a mobile phase gradient. The
mass spectrometer was operated in positive electrospray ion-
ization mode. The multiple reaction monitoring transition ions
were m/z 640.3/303.3 for Bendavia. Peak-area integration
was performed with Analyst software (version 1.5, Applied
Biosystems).
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The measured Bendavia concentration (in nanograms per
milliliter) of each sample was converted to nanomolar (nmol/L)
concentration by using molar weight of the free peptide
(639.8 g/mol). Organ uptake (%) was calculated by using the
standard formulation:
Organ uptake (%) = Input(
nmol/L) − Output(nmol/L)
Input(nmol/L)
× 100%
where Input is the Bendavia concentration in the perfusate
buffer and Output is the Bendavia concentration in the pul-
monary artery (coronary effluent). Uptake data are expressed
as the percentage of Input Bendavia retained by the organ
during single-pass perfusion.
Myocyte Hypoxia/Reoxygenation Experiments
Guinea pig LV myocytes were isolated enzymatically from
a total of 17 animals according to established protocols.18
Isolated primary cardiomyocytes were enzymatically isolated
and incubated (95% O2 balance room air, 37◦C) for 2 to
8 hours after dispersion. For cellular hypoxia/reoxygenation
studies, isolated myocytes were placed in a perfusion cham-
ber housed on the stage of a fluorescence microscope (Le-
ica) for the study of cell survival and ROS production during
cellular hypoxia/reoxygenation. The small-volume perfusion
chamber (250 μL) used in the study is enclosed in glass to
minimize gas exchange with the environment and is equipped
with pacing electrodes for field stimulation (Warner Instru-
ments). The chamber is housed on the microscope stage by a
magnetic holder with heating filaments, allowing us to con-
duct our measurements at 37◦C, and is connected to an
in-line solution heater that delivers the superfusate via lab-
oratory tubing that has very low oxygen permeability (Tygon
F-4040-A).
For each myocyte experiment, cells were allowed to set-
tle on the glass coverslips for ≥20 minutes before the initi-
ation of perfusion. Differential interference contrast images
of the myocytes were obtained at the beginning and end
of each experiment. Cells were perfused with Tyrode’s solu-
tion containing (in mmol/L): 140 NaCl, 10 HEPES, 5 KCl, 1
MgCl2, 1.8 CaCl2, and 10 glucose (pH=7.4, 37◦C), delivered
at a rate of 1.0 to 1.2 mL/min. Only rod-shaped myocytes
that were responsive to field stimulation (an assessment of
cell viability) were selected for hypoxia/reoxygenation stud-
ies. Myocytes were paced (4-ms duration, 1-Hz frequency,
10-V amplitude) for the duration of the hypoxia/reoxygenation
protocol on the basis of observations that guinea pig my-
ocardium maintains electrical activity through 20 minutes of
ischemia.19
For the drug treatment groups, myocytes either were in-
cubated for 10 minutes with 1 nmol/L Bendavia before be-
ing placed in the perfusion chamber (Bendavia group) or re-
ceived no drug treatment (Control group). Myocytes received
5 minutes of baseline superfusion, after which the solution
was switched to Tyrode’s solution gassed with 100% argon
(hypoxia solution) for 20 minutes. After 20 minutes of perfu-
sion with hypoxia solution, the superfusate was switched back
to normoxic Tyrode’s to initiate reoxygenation. Cells were re-
oxygenated for 30 minutes or until cell death, whichever came
first. When appropriate, the time of myocyte death during hy-
poxia/reoxygenation was noted by complete transition from
rod-shaped to rounded, necrotic cell morphology.
Subsets of myocytes that underwent hypoxia/reoxy-
genation were loaded with one of 2 fluorescent probes.
Cells either received the ROS probe 5-(6)-chloromethyl-2,7-
dichlorohydrofluorescein diacetate (CM-DCF, Invitrogen), or
the m sensor tetramethylrhodamine methyl ester (TMRM,
Sigma) during the protocol. Another cohort of cells was ex-
posed to hypoxia/reoxygenation with no fluorescent probe to
determine if the fluorophores themselves influenced cell sur-
vival. Because the different flouorophores did not influence the
proclivity to cell death during the protocol (when compared to
unloaded cells), the data were pooled for the survival plot to
include all cells exposed to hypoxia/reoxygenation.
Cellular Hypoxia/Reoxygenation and
Simultaneous ROS Production
Ventricular cardiomyocytes were loaded with 500 nmol/L of
the fluorescent ROS probe CM-DCF (Invitrogen) for 10 minutes
in the incubator before imaging. A subset of myocytes was in-
cubated for 10 minutes with 1 nmol/L Bendavia (in addition
to CM-DCF), also in the incubator. CM-DCF fluorescence was
evoked by using light from ametal-halide lamp filtered to an ex-
citation wavelength of 472 nm (band-pass filter width 30 nm),
and emission was collected at 520 nm (band-pass filter width
36 nm). Emitted light was captured with a charge-coupled
device camera, and images were acquired on a personal com-
puter. To avoid photobleaching of the probe, sampling rate
was set at 30-second intervals for the duration of the pro-
tocol. Our preliminary data indicated that this sampling rate
and fluorophore concentration led to stable recordings in nor-
moxic (nonstressed) myocytes for up to 50 minutes (data not
shown).
For the CM-DCF analysis, changes in fluorescence inten-
sity were quantified for each time point by subtracting the cell
fluorescence (obtained via a region of interest drawn around
the cell perimeter) from background fluorescence (obtained
via a region of interest in an area adjacent to each myocyte).
To account for unequal fluorophore loading across cells, each
cellular fluorescence trace was normalized to baseline (pre-
hypoxia) fluorescence intensity (Fo) for each cell. Cell survival
was monitored on the computer screen as the ROS signal was
captured.
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Figure 1. Left, Ischemic risk zone (% LV) and infarct size (% risk zone) in sheep exposed to
in vivo ischemia/reperfusion (60 min/3 h). Bendavia (0.05 mg/kg per hour; black bars) was
administered intravenously beginning 30 minutes before reperfusion (mean±SEM; P=0.02,
t test). Right, Relationship between the extent of the ischemic risk zone (% LV) and the extent of
necrosis (% LV) (P=0.03, ANCOVA).
Mitochondrial Membrane Potential (m) During
Hypoxia/Reoxygenation
Separate experiments were conducted to determine the
influence of Bendavia on m during cellular hypoxia/
reoxygenation. Isolated guinea pig ventricular myocytes were
loaded with the m sensor TMRM for 10 minutes before
imaging. We used a TMRM concentration of 25 nmol/L, which
is “nonquench” mode in this application. TMRM fluorescence
was evoked by using an excitationwavelength of 560 nm (band-
pass filter width 40 nm), and emission was collected at 645 nm
(band-pass filter width 72 nm). TMRM fluorescence intensity
was captured every 60 seconds throughout hypoxia and reoxy-
genation or until cell death, whichever came first.
Statistical Analyses for Guinea Pig Studies
The myocyte survival curve was analyzed with a log-rank
(Mantel-Cox) test. Infarct size and Bendavia uptake data for
the guinea pig hearts were analyzed by ANOVA, followed by
Newman-Keuls post hoc tests for between-group comparisons.
For all comparisons, significance was noted if P<0.05.
Results
Effect of Bendavia on Ischemia/Reperfusion
Injury Across Models
The effect of Bendavia on infarct size in sheep is presented in
Figure 1 left. The ischemic AAR was similar in both groups,
comprising 24.0±0.7% of the LV in the vehicle group and
23.1±0.7% in the Bendavia-treated group. Treatment with
Bendavia significantly reduced infarct size by 15.4%, from
64.1±1.5% of the risk zone in the vehicle group to 54.2±3.5%
in Bendavia-treated sheep (P=0.02). Overall, for any given
risk zone size, the extent of necrosis
was lower in Bendavia-treated hearts
(P=0.03; Figure 1 right).
In the rabbit model, the size of is-
chemic risk zone, expressed as a frac-
tion of the LV, was similar in all groups
(average of 0.30 to 0.32;P=NS). There
were no statistically significant differ-
ences in mean values among the 4
groups in infarct size expressed as a
fraction of the risk zone (Table 1). To
assess the overall effects of treatment
with Bendavia when administered af-
ter the onset of CAO but before reper-
fusion, infarct size from the 3 treated
groups was combined and compared
with that from the control group.
Overall, there was a nonsignificant 11% reduction in infarct
size with Bendavia treatment. A post hoc analysis was
performed to examine infarct size in rabbits with larger
infarcts (>20% of the LV; Table 2 and Figure 2) to paral-
lel the sheep model, in which the risk regions were gen-
erally ≥20% of the LV. Infarct size in Bendavia-treated an-
imals was reduced by 17.5%, from 0.40±0.03 of the is-
chemic risk zone to 0.33±0.02, resulting in a strong statistical
trend (P=0.09) and consistent with the degree of myocardial
Table 1. Risk Zone and Infarct Size in the Rabbit Model: 4
Treatment Groups
Group 1
(n=15)
Group 2
(n=17)
Group 3
(n=17)
Group 4
(n=15) P
Risk zone 0.30±0.02 0.32±0.02 0.31±0.02 0.30±0.02 0.89
Infarct size 0.33±0.03 0.32±0.04 0.31±0.04 0.36±0.04 0.74
Risk zone is given as fraction of LV; infarct size, fraction of risk zone.
Treatment groups: Group 1 received Bendavia starting at 20 minutes before coronary
artery reperfusion; Group 2 received Bendavia starting at 10 minutes before
reperfusion; Group 3 received Bendavia starting 1 minute before reperfusion; and
Group 4 received saline. See text for details.
Table 2. Risk Zone and Infarct Size in Combined Treatment
Group Versus Vehicle
Bendavia Vehicle P
Risk zone ≥10% of LV n=49 n=15
Risk zone 0.31±0.01 0.30±0.02 0.65
Infarct size 0.32±0.02 0.36±0.04 0.30
Risk zone ≥20% of LV n=46 n=13
Risk zone 0.32±0.01 0.33±0.02 0.84
Infarct size 0.33±0.02 0.40±0.03 0.09
Risk zone is given as fraction of LV; infarct size, fraction of risk zone.
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Figure2. Left, Ischemic risk zone (fraction LV) and infarct size (fraction risk zone) in rabbitswith
risk zones >20% of the LV exposed to in vivo ischemia/reperfusion (30 min/3 h) in combined
Bendavia treatment group and vehicle group (mean±SEM; P=0.09, t test). Note similarity to
data observed in the sheep model (text, Figure 1). Right, Relationship between the extent of the
ischemic risk zone (g) and the extent of necrosis (g) in combined Bendavia group and vehicle
group. Regression lines: vehicle is indicated by dashed line; Bendavia, solid line.
Figure 3. Infarct size in isolated guinea pig hearts exposed to global
ischemia/reperfusion (20 min/2 h). Experimental compounds were
either administered both before and after ischemia (whole time)
or administered only at the onset of reperfusion (@ reperfusion)
(mean±SEM; P<0.05 vs control, ANOVA followed by Newman-Keuls
post hoc tests for between-group comparisons).
protection demonstrated with sheep (Figure 1). Interestingly,
Bendavia-induced reductions in infarct size appeared to be
more prominent in hearts with larger at-risk zones, consistent
with previous studies indicating that cardioprotective strate-
gies may be most effective when the zone at risk is larger.20,21
The effect of Bendavia on infarct size in guinea pigs is pre-
sented in Figure 3. In this model, the entire LV is hypoxic,
so the risk area consists of the entire LV mass. After the is-
chemia/reperfusion protocol, untreated (control) guinea pig
hearts had infarct sizes of 50±4% of
the AAR (n=14, Figure 3). Adminis-
tration of 1 nmol/L Bendavia, either
before ischemia (n=9) or at the onset
of reperfusion only (n=9), significantly
reduced infarct size to 29±6% and
31±6% AAR, respectively (P<0.05
versus control, ANOVA). Treatment
with 0.2 μmol/L cyclosporine A at
the onset of reperfusion also signifi-
cantly reduced infarct size to 33±5%
of the AAR (P<0.05 versus control,
ANOVA; n=8). There were no differ-
ences in infarct size among treat-
ment groups. Moreover, reductions
in infarct size were more prominent,
with larger at-risk zones in guinea
pigs than in sheep and rabbits.20,21
Effect of Bendavia on Coronary No-Reflow
In the rabbit model, Bendavia significantly reduced the extent
of no-reflow expressed as a percentage of the risk zone when
the relationship between the extent of the risk zone and the
extent of the no-reflow area in the 4 groups was analyzed by
ANCOVA testing for group as a covariate effect (P=0.036).
The mean value of no-reflow, expressed as a fraction of the
risk region, was 0.22±0.02 in the combined Bendavia groups
versus 0.28±0.03 in the control group (P=0.07). There was
a significant group effect on the relationship between the no-
reflow zone and the risk zone (P=0.0085, combined Bendavia
versus vehicle; Figure 4). The regression line for the treated
hearts lies below that of the control hearts. That is, for any given
risk zone, the extent of no-reflow was significantly smaller in
Bendavia-treated animals.
Effects of Bendavia on Postischemia
Hemodynamic Recovery and Arrhythmia
Across models, Bendavia had no major effects on the
recovery of cardiac electromechanical function after is-
chemia/reperfusion. In sheep studies, treatment with Ben-
davia had no significant effect on heart rate, mean arterial
pressure, mean pulmonary artery pressure, pulmonary wedge
pressure, central venous pressure, or cardiac output as com-
pared with the vehicle group. In rabbit studies, there were no
significant differences among groups in heart rate or blood
pressure.
In guinea pig experiments, neither the incidence of arrhyth-
mia nor the extent of recovery of LV function was influenced by
Bendavia treatment. Arrhythmia scores for the 2-hour reper-
fusion period were 4.9±0.4 in the control group (n=14).
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Figure 4. Relationship between risk zone (g) and the extent of no-
reflow (g). Lines of regression for vehicle-treated rabbits (dashed line)
and Bendavia-treated rabbits (solid line) are shown. *P=0.0085 by
ANCOVA testing for a treatment effect (Bendavia vs vehicle) on the
relationship.
Administration of Bendavia, either before ischemia or at the
onset of reperfusion, had no effect on arrhythmia scores
(5.8±0.7 and 4.4±0.4, respectively, n=9 and 9, respectively;
P>0.05, ANOVA). Cyclosporin A treatment also had no signif-
icant effect on the incidence of arrhythmia (arrhythmia score
of 4.0±0.5, n=8; P>0.05, ANOVA). LV developed pressure
at the end of the 2-hour protocol was 23±5 mm Hg in the
control group (n=14) and 24±6 mm Hg when Bendavia was
administered during both ischemia and reperfusion (n=9). Ad-
ministration of Bendavia or cyclosporine A at the onset of reper-
fusion also had no effect on recovery of developed pressure
(39±5 and 34±6 mm Hg, n=9 and 8, respectively; P>0.05,
ANOVA).
Myocardial Uptake of Bendavia
Cardiac uptake of Bendavia is presented in Figure 5. The guinea
pig myocardium extracted ≈25% of Bendavia per minute from
the perfusate, and there were no differences in the rate of
uptake between baseline perfusion and the reperfusion period
(P>0.05, ANOVA).
Guinea Pig Myocyte Survival During
Hypoxia/Reoxygenation
In this study, a total of 78 guinea pig cardiac myocytes were
exposed to cellular hypoxia/reoxygenation. Because cells died
during both the hypoxic and reoxygenation periods, a cell
survival plot is presented in Figure 6. A total of 43 cells
were exposed to hypoxia/reoxygenation under control (no-
drug) conditions, whereas another 35 cells were treated with
1 nmol/L Bendavia. At the end of the 20-minute hypoxia pe-
Figure 5. Uptake of Bendavia by the myocardium before ischemia
(Baseline) and during reperfusion. Data represent the percentage of
Bendavia taken up by the heart over a 1-minute time course.
Figure 6. Survival plot for myocytes in the study exposed to hypoxia
and reoxygenation. Each cell death event is noted as a downward step
in the survival curve. *P<0.02, log-rank (Mantel-Cox) test vs control
for the reoxygenation period. Bendavia significantly lowered cell death
rate during reoxygenation, but the extent of cell death during hypoxia
was similar to control.
riod, 65% of control cells (28 of 43 total) and 74% of Bendavia-
treated cells (26 of 35 total) were still alive (no drug effect
during hypoxia; P>0.05, Mantel-Cox test). Bendavia specif-
ically prevented death associated with reoxygenation. After
reoxygenation, there was a significant decrease in cell death
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Figure 7. Cellular ROS production during hypoxia/reoxygenation. A, Representative fluorescence
images of cardiac ventricular myocytes loaded with the ROS sensor CM-DCF. ROS bursts during
reoxygenation preceded cell death, and Bendavia treatment prevented ROS-induced cell death.
B, Representative fluorescence intensity traces for cells in the study. CM-DCF fluorescence is
normalized to the basal fluorescence (Fo) for each cell at the end of hypoxia. C, Contribution of ROS
bursts to myocyte death during hypoxia/reoxygenation.
evoked by Bendavia. Of the cells
that were alive at the onset of
reoxygenation, only 54% of control
cells survived until the end of
reoxygenation, compared to 85%
of cells that were treated with
Bendavia (P<0.02, Mantel-Cox
test).
Role of Mitochondrial ROS
in Cell Death
A subset of myocytes (n=35 total)
exposed to hypoxia/reoxygenation
were loaded with the ROS sen-
sor CM-DCF during the protocol
to monitor ROS production with
(n=18) or without (n=17) Ben-
davia pretreatment. Figure 7 de-
picts the incidence of a preceding
ROS burst before cell death. The
majority of cell death in the con-
trol group was preceded by a burst
of ROS during the reoxygenation
period. ROS-dependent cell death
was completely prevented in my-
ocytes treated with Bendavia (Fig-
ure 7B and 7C). ROS-independent
cell death during hypoxia or re-
oxygenation was similar between
the control and Bendavia-treated
groups. The time course for ROS
bursts in our model (as assessed
by DCF fluorescence) ranged be-
tween 1 and 19 minutes of reper-
fusion, with most bursts occurring
between minutes 5 and 15 of re-
oxygenation.
Maintenance of
Mitochondrial Membrane
Potential (m)
Another subset of myocytes (n=37
total) was exposed to hypoxia/
reoxygenation while loaded with
the m indicator TMRM (pre-
sented in Figure 8). Myocytes
treated with Bendavia were
protected against cell death
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Figure 8. Mitochondrial membrane potential (m) in myocytes during cellular hy-
poxia/reoxygenation. A, Representative fluorescence images of myocytes loaded with the m
sensor TMRM. m collapse often preceded cell death, and treatment with Bendavia improved
the capacity to maintain m. B, Representative fluorescence intensity traces for cells in the
study.
during reoxygenation, and specifically against cell death that
was preceded by a collapse of m. Only 14% of cells in
the Bendavia-treated group displayed a collapse in m be-
fore cell death, compared to 42% of untreated cells. These
data suggest that Bendavia helped promote cell survival by
sustaining mitochondrial energetics (m) during reoxygena-
tion and decreasing the overall incidence of permeability
transition.
Discussion
Key Findings
Numerous agents have been tested as adjunctive therapy for
reperfusion injury in the setting of acute myocardial infarction.
At the present time, early reperfusion via thrombolytic ther-
apy or percutaneous coronary intervention (including percuta-
neous transluminal coronary angioplasty) is the only accepted
definitive therapy for acutemyocardial infarction.22 Early reper-
fusion limits myocardial infarct size and improves survival rate.
Nevertheless, not all patients receive
early coronary artery reperfusion,
and at the time of reperfusion some
degree of injury may occur as a result
of reperfusion itself. Stunned my-
ocardium, the no-reflow phenomenon,
microvascular injury, and reperfusion
arrhythmias are forms of reperfusion
injury.
The present studies show that Ben-
davia, administered after the onset of
ischemia, demonstrated cardioprotec-
tive effects in several diverse models
of ischemia/reperfusion. Bendavia re-
ducedmyocardial infarct size in a large
animal model (sheep), attenuated the
extent of no-reflow in an in vivo rab-
bit model, and reduced infarct size in
isolated guinea pig hearts. Bursts of
ROS were blunted by Bendavia, result-
ing in bettermaintenance ofmitochon-
drial energetics and lowered cell death
during reoxygenation. Finally, we ob-
served that myocardial uptake of Ben-
davia is high even during early reperfu-
sion, indicating that this compound is
actively taken up by myocardium even
if the tissue has been exposed to an
ischemic insult.
Cardioprotection at Reperfusion: “Salvaging Cells
That Are Salvageable”
Cell death during ischemia and reperfusion is multifactorial
and is generally attributed to a combination of necrosis and
apoptosis,23 with necrotic cell death being the predominant
cause of death in ischemic myocardium.24 Although reperfu-
sion is requisite to salvage tissue, prompt reperfusion also
may injure cells that are hovering between life and death. El-
evated intracellular levels of calcium, sodium, and inorganic
phosphate, an alkaline shift toward physiological pH, and pro-
duction of ROS are all noted in early reperfusion.23 These
factors promote the opening of energy-dissipating channels
in the inner mitochondrial membrane. In particular, the open
probability of both the mitochondrial permeability transition
pore (reviewed in Halestrap et al10) and the inner membrane
anion channel (reviewed in Brown et al25) is greatly enhanced
by ROS. Oxidant-induced pore/channel opening collapses mi-
tochondrial membrane potential (m), leading to cessa-
tion of adenosine triphosphate production and ultimately cell
death.
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The Mitochondria as a Therapeutic Target
In the clinical realm, heightened ROS production is implicated
in the development of both infarction and the microvascular
damage that underlies coronary no-reflow.8,23 There is obvi-
ously a great deal of interest in decreasing reperfusion in-
jury with compounds that scavenge reactive intermediates
or directly block the permeability transition pore. Among the
candidate radical scavengers tested to date, early efforts fo-
cused primarily on superoxide dismutase mimetics and cata-
lase. These approaches reduced infarct size in some26–29 (but
not all30) animal studies and also decreased microvascular
damage and reduced no-reflow.30 Despite promising results
in animal studies, these strategies do not appear to translate
to beneficial effects in clinical trials.31,32 The reasons for the
lack of translation to the clinic have been described in detail
elsewhere20,33 but likely involve cell permeability concerns, as
well as findings that nonspecific radical scavengers must be
used in very high doses for efficacy to be seen. Furthermore,
superoxide dismutase mimetics scavenge only superoxide an-
ion, whereas a significant portion of tissue injury may arise
from radical-independent redox signaling (ie, oxidative shifts
in intracellular thiols).34
Direct permeability transition pore blockers have recently
shown potential in reducing reperfusion injury in animal and
human studies. Cyclosporin A, which inhibits the association
of cyclophilin D with the mitochondrial permeability transition
pore, has been shown to reduce cardiac ischemia/reperfusion
injury35,36 (Figure 3). In a recent small clinical trial,21 cy-
closporine given at the time of percutaneous coronary inter-
vention significantly reduced infarct size (assessed with both
magnetic resonance imaging and enzymatic markers in serum)
in humans, corroborating previous data from studies in an-
imals. A multicenter clinical trial is currently under way in
Europe to investigate cyclosporin in a larger population of
myocardial infarct patients. Although these early results are
promising, the use of cyclosporin may be limited by a narrow
therapeutic window,37 nonspecific effects on other cellular
cyclophilins/calcineurin,38 and reports of cyclosporin-induced
vasoconstriction.39
Reduction of Infarction With Bendavia
A clear need exists for cytoprotective compounds that freely
cross the sarcolemma, are effective across low doses, and
specifically target the region within the cell where oxidant pro-
duction is high (specifically, the mitochondria). Drs Hazel H.
Szeto and Peter W. Schiller developed a unique class of pep-
tides that concentrate within mitochondria and reduce ROS
generation in cultured cells exposed to chemical oxidative
stress.13,40 Bendavia (an analogue of SS-02 and SS-31 in the lit-
erature) is a novel peptide that is able to cross cell membranes.
In particular, studies using colocalization confocal imaging and
radiolabeled peptide uptake indicated that Bendavia localizes
to (and accumulates within) mitochondria,12,41 making it an
attractive therapy to reduce mitochondria-derived ROS.
From a therapeutic standpoint, Bendavia uptake appears
to be independent of the m. m collapses during is-
chemia, and the recovery of m at reperfusion is very het-
erogeneous in the myocardium.42,43 Treatment strategies that
require m for mitochondrial delivery (such as antioxidants
conjugated to triphenylphosphonium cations, eg, SkQ1, Mi-
toQ, MitoE, MitoSOD44) may only be targeting only cells that
are already on their way to recovery. In our study, myocardial
uptake of Bendavia was observed even in early reperfusion
(when m may be compromised), consistent with studies in
isolated cells where accumulation was not markedly affected
by chemical uncouplers of mitochondria.12 Furthermore, the
m-depolarizing effects of compounds tethered to triph-
enylphosphonium make them self-limiting and translate to a
very narrow therapeutic window of efficacy.13 Bendavia treat-
ment has no noticeable effect on basal m when assessed
by either TMRM fluorescence12 or triphenylphosphonium up-
take (D.A. Brown, unpublished observations), allowing for a
very wide therapeutic range and cardioprotection at or below
nanomolar concentrations (Zhao et al12 and herein).
In the present study, we show for the first time that Ben-
davia treatment reduced cellular ROS generation and helped
sustain m in primary cardiac myocytes exposed to hy-
poxia/reoxygenation. In particular, Bendavia reduced oxidant-
dependent cell death during the reoxygenation period yet had
no effect on myocyte survival during hypoxia. This finding sup-
ports our hypothesis that this compound is most effective
when production of ROS is high and needs to be suppressed
or ablated at the site of generation (ie, the mitochondria). The
time course of ROS burst and myocyte death that we observed
is generally consistent with studies in the literature that have
used both in vivo and isolated heart models. Two different
studies found that the burst of ROS (assessed by electron spin
resonance spectroscopy) remained high for the first 20 min-
utes of reperfusion, after which the burst waned.45,46 In both of
these studies, ROS levels peaked within the first 5 minutes and
remained significantly elevated through the first 20 minutes of
reperfusion. We also found that ROS bursts were highest in
the first 20 minutes of reoxygenation, although the timing of
ROS bursts was slightly delayed in our model compared to
intact systems (most ROS-dependent cell death occurred be-
tween minutes 5 and 15 of reoxygenation in our study). A likely
explanation for this discrepancy is that our isolated myocytes
were not loaded, and thus the energetic needs of the myocytes
were lower than they would be in an intact syncytium, which
ostensibly prolonged the tolerance to metabolic insult in our
model.
Our myocyte data corroborate previous work in cell cul-
ture models, where Bendavia lowered the levels of ROS and
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promoted cellular survival in neuronal cells exposed to t-
butylhydroperoxide.12 It seems plausible that by keeping ROS
low, either by inhibiting the initiation and cascade of ROS pro-
duction or by mitochondrial ROS scavenging, Bendavia main-
tains m by reducing the open probability of (1) energy-
dissipating ion channels in the inner membrane and (2) the
permeability transition pore. With regard to the effects of Ben-
davia on the permeability transition pore, we recently directly
examined the effects of Bendavia on calcium-induced perme-
ability transition pore opening in isolated mitochondria. Ben-
davia does not appear to be a direct blocker of the pore,
as opposed to blockers such as cyclosporin-A or NIM811.47
Therefore, the maintenance of myocyte energetics (m) that
we observed in our study seems to be an indirect effect of Ben-
davia (by keeping ROS low), rather than a direct effect on the
pore.
The cardioprotection that we observed in isolated guinea
pig cells translated to infarct-size reduction in several models
of ischemia/reperfusion. Notably, in each case, the protection
was observed when Bendavia was given after the onset of
ischemia. These data support the concept that damage to
the mitochondria at the time of reperfusion is therapeutically
preventable.
Bendavia Protection Against the No-Reflow
Phenomenon
Our study is also the first to demonstrate a beneficial effect
of Bendavia on the no-reflow phenomenon. No-reflow is the
phenomenon whereby portions of a myocardial infarction can-
not be reperfused despite the fact that the epicardial infarct-
related artery has been successfully reopened and remains
patent. The cause of no-reflow is primarily microvascular ob-
struction due to localized and regional swelling of the endothe-
lium. No-reflow has been identified in humans after myocardial
infarction by using a number of techniques, including magnetic
resonance imaging, echo contrast, and nuclear scanning.48
Because the zone of no-reflow is cut off from blood supply,
no-reflow may impede the healing phase of infarction. In both
experimental and clinical studies, no-reflow is associated with
more myocardial infarct expansion, worse LV dilation and re-
modeling, and more congestive heart failure and death.5,48 At
the present time, there are no FDA-approved drugs for the
treatment of no-reflow. In our study, for any given ischemic
risk zone size, Bendavia decreased no-reflow. This indepen-
dent effect on no-reflow for any given risk zone is one of the
first demonstrations of its kind for a cardioprotective agent
in the present model and is consistent with results previously
seen only with hypothermia induced before reperfusion.
Why should an agent that targets the mitochondria have
this effect on the vasculature? Mitochondrial ROS production
by endothelial cells during early reperfusion contributes to
microvascular damage associated with no-reflow.49 Isolated
endothelial cells exposed to hypoxia/reoxygenation display
increased mitochondrial ROS levels after reoxygenation, and
inhibitors of mitochondrial electron flow reduced endothelial
ROS production.50 Our study is the first to extrapolate these
findings from cultured cells to an intact mammalian (rabbit)
model of ischemia/reperfusion, demonstrating that targeting
and preventing endothelial mitochondrial ROS during early
reperfusion functionally reduces no-reflow. Moreover, our use
of Bendavia, which is effective at low doses and has no ef-
fect on normal mitochondrial respiration,12 represents a sig-
nificant advancement over more toxic approaches that reduce
endothelial ROS by directly blocking mitochondrial respiration.
Study Limitations
The reduction of myocardial infarct size in the sheep model
was modest, as was the trend toward reduction in the rabbit
model. In the isolated guinea pig hearts, the reduction in infarct
size was more robust. Although other drugs may have shown
greater reductions in infarct size,51,52 the directional change
was similar in 3 separate species studied in 3 separate lab-
oratories. It is possible that small sample sizes might explain
the fact that some of the comparisons failed to reach statis-
tical significance. Whether Bendavia would have any effect in
patients is unknown.
There are examples in the clinical literature in which the
reduction of infarct size was modest—for example, remote
ischemic conditioning, which reduced troponin T release by
16%.53 Several meta-analyses have examined the reduction in
infarct size associated with bone marrow–derived stem cell
therapy, showing modest reductions of infarct size of 6% and
7%,54,55 but this was associated with long-term improvement in
ejection fraction. We would not expect improvement in func-
tional recovery in the type of short-term studies described
in the present article because the salvaged peri-infarct my-
ocardium remains stunned for days to weeks after reperfusion.
Hence, to determine whether Bendavia improves cardiac func-
tion in an infarct model would require a long-term study. We
did not specifically study Bendavia in a stunned myocardium
model, which would require studying a brief period of transient
ischemia (5 to 15minutes) that is not associated with necrosis.
Another critical component of ischemia/reperfusion injury is
related to calcium overload, which contributes to opening of
the mitochondrial permeability transition pore.56 We did not
specifically study whether Bendavia limits calcium overload,
but this would be of interest in future studies.
Summary
In conclusion, the mitochondria-targeting agent Bendavia
demonstrated cardioprotective properties in several in vitro
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and in vivo experimental models when administered before
reperfusion. It protected cardiomyocytes; it limited myocar-
dial infarct size; and for the first time it was shown to limit
no-reflow.
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